Buradasınız

Anasayfa » Content

Primer Hipertansiyonlu Hastalarda Trandolaprilin Tek Başına ve Verapamil ile Birlikte Kullanımının İdrar Protein Atılımı Üzerine Etkisinin Karşılaştırılması

The Comparison of Effect of Trandolapril Alone and Combined With Verapamil on Urinary Protein Excretion in Patients With Primary Hypertension

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Angiotensin converting enzyme inhibitors and calcium channel blockers are the most frequently used antihypertensive agents. Both drug groups are combined recently. In this study we compared the antihypertensive and antiproteinuric efficacies of trandolapril and trandolapril plus verapamil combination in primary hypertensive patients. Twenty nine hypertensive patients were included in the study. These patients were mildly or moderately hypertensive and were not using antihypertensive medication before the study. They were randomly divided into two groups. 15 patients in the 1 st group received trandolapril 2 mg/day and 14 patients in the 2 nd group 2 mg/day trandolapril plus 180 mg/day verapamil combination for 3 months. Renal functions, daily proteinuria excretions and creatinine clearences were evaluated before and after treatment. The blood pressures decreased significantly in both groups, but there was no change in the other parameters studied. Additionally, there was no significant difference between values of both groups before and after the treatment. As a result, it was concluded that both protocoles did not affect urinary protein excretion in short term usage.
Bookmark/Search this post with
Abstract (Original Language): 
Angiotensin dönüştürücü enzim inhibitörleri ve kalsiyum kanal blokerleri hipertansiyon tedavisinde en yaygın kullanılan ilaçlardır. Son yıllarda her iki ilaç grubu kombine edilerek kullanılmaktadır. Bu çalışmada primer hipertansiyonlu hastalarda trandolapril ve trandolapril + verapamil kombinasyonunun antihipertansif ve antiproteinürik etkinlikleri karşılaştırıldı. Çalışmaya 29 hipertansif hasta alındı. Hafif veya orta derecede hipertansif olup önceden herhangi bir antihipertansif tedavi kullanmayan olgular seçildi. Olgular rastgele iki gruba ayrıldılar. Birinci grupta 15 hasta 2 mg/gün trandolapril, 2. grupta 14 hasta 2 mg/gün trandolapril + 180 mg/gün verapamil kombinasyonunu 3 ay süreyle aldılar. Hastaların tedavi öncesi ve sonrası kan basınçları, renal fonksiyonları, günlük protein atılımları ve kreatinin klirensleri değerlendirildi. Her iki grupta da kan basınçları anlamlı olarak düştü. Ancak değerlendirilen diğer parametrelerde tedavi sonrası anlamlı bir deği- şiklik gözlenmedi. Ayrıca her iki grubun tedavi öncesi ve sonrası değerleri arasında anlamlı bir fark yoktu. Sonuç olarak her iki tedavi protokolünün kısa dönemde idrar protein atılımını etkilemediği kanaatine varıldı
FULL TEXT (PDF): 
PDF icon arastirmax-primer-hipertansiyonlu-hastalarda-trandolaprilin-tek-basina-verapamil-ile-birlikte-kullaniminin-idrar-protein-atilimi-uzerine-etkisinin-karsilastirilmasi.pdf
  • 3
143-146
  • Turkish

REFERENCES

References: 

1. Tuncel E, Güçlü M. Diyabet ve nefropati. İçinde: Imamoğlu S
(Ed). Diabetes Mellitus 2006. İstanbul: Elif Ofset, 2006:295-
309.
2. Ruschitzka FT, Noll G, Lüscher TF. Combination of ACE
inhibitors and calcium antagonists: a logical approach. J
Cardiovasc Pharmacol 1998;31(Suppl 2):S5-16. A. Ersoy, ark.
146
3. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of
an ACE inhibitor/calcium antagonist combination on
proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9.
4. Cetinkaya R, Odabas AR, Selcuk Y. Anti-proteinuric effects of
combination therapy with enalapril and losartan in patients with
nephropathy due to type 2 diabetes. Int J Clin Pract
2004;58:432-35.
5. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A.
Differential effects of calcium antagonist subclasses on markers
of nephropathy progression. Kidney Int 2004;65:1991-2002.
6. Gransevoort RT, Sluiter WJ, Hemmelder MH, et al.
Antiporoteinuric effect of blood-pressure lowering agents: A
metaanalysis of comparative tirals. Nephrol Dial Transplant
1995;10:1963-74.
7. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term Effects of
antihypertensive agents on proteinuria and renal function. Arch
Intern Med 1995;155:1073-80.
8. Gansevoort RT, de Zeeuw D, de Jong PE. Dissociation between
the course of the hemodynamic and antiproteinuric effects of
angiotensin I converting enzyme inhibition. Kidney Int
1993;44:579-84.
9. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S.
Calcium channel blockers versus other antihypertensive
therapies on progression of NIDDM associated nephropathy.
Kidney Int 1996;50:1641-50.
10. Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric
efficacy of verapamil in comparison to trandolapril in nondiabetic renal disease. Nephrol Dial Transplant 1999;14:98-104.
11. PROCOPA Study Group. Dissociation between blood pressure
reduction and fall in proteinuria in primary renal disease: a
randomized double-blind trial. J Hypertens 2002;20:729-37.
12. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment
of diabetic renal disease in type 2 diabetes: the BENEDICT
study. J Am Soc Nephrol 2006;17(4 Suppl 2):S90-7.
13. Cooper-DeHoff RM, Handberg EM, Mancia G, et al. INVEST
revisited: review of findings from the International Verapamil
SR-Trandolapril Study. Expert Rev Cardiovasc Ther
2009;7:1329-40.
14. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus
amlodipine or hydrochlorothiazide for hypertension in high-risk
patients. N Engl J Med 2008;359:2417-28.
15. Sica D. Calcium channel blockers and the kidney. Clin
Cornerstone 2004;6:39-52.
16. Pedrinelli R. Microalbuminuria in hypertension. Contrib
Nephrol 1996;119:103-9.
17. Derici U, Sindel S, Arinsoy T, et al. Effects of verapamil slow
release plus trandolapril combination therapy on essential
hypertension. Curr Ther Res 2003;64:10-20.

Thank you for copying data from http://www.arastirmax.com